{"version":"1.0","provider_name":"Revista Brasileira de Oftalmologia","provider_url":"https:\/\/www.rbojournal.org\/en\/","title":"Sin\u00e9quia iriana no Xen45 Gel Stent - Revista Brasileira de Oftalmologia","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"rYVnsTnThW\"><a href=\"https:\/\/www.rbojournal.org\/en\/article\/sinequia-iriana-no-xen45-gel-stent\/\">Sin\u00e9quia iriana no Xen45 Gel Stent<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.rbojournal.org\/en\/article\/sinequia-iriana-no-xen45-gel-stent\/embed\/#?secret=rYVnsTnThW\" width=\"600\" height=\"338\" title=\"&#8220;Sin\u00e9quia iriana no Xen45 Gel Stent&#8221; &#8212; Revista Brasileira de Oftalmologia\" data-secret=\"rYVnsTnThW\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.rbojournal.org\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.rbojournal.org\/wp-content\/uploads\/2023\/10\/0034-7280-rbof-82-e0053-gf01-768x434.jpg","thumbnail_width":600,"thumbnail_height":339,"description":"Paciente, 73 anos, sexo masculino, pardo, portador de glaucoma prim\u00e1rio de \u00e2ngulo aberto moderado, pseudof\u00e1cico, foi submetido \u00e0 cirurgia microinvasiva do glaucoma com implante Xen45 Gel Stent (AbbVie Inc., Illinois, Estados Unidos) em olho esquerdo. A press\u00e3o intraocular (PIO) pr\u00e9-operat\u00f3ria era 23mmHg, com tr\u00eas classes de medicamentos para glaucoma (maleato de timolol 0,5% + cloridrato de dorzolamida 2% + latanoprosta 0,005%). [&#8230;]"}